Infusional C-myb ASODN in Advanced Hematologic Malignancies
The purpose of this study is to evaluate whether C-myb Antisense (AS) Oligonucleotides (ODNs)is a possible treatment modality for advanced hematologic malignancies.
Hematologic Malignancies
DRUG: c-myb AS ODN
Dose-limiting toxicities and maximum tolerated dose and maximum tolerated duration of c-myb AS ODN, At study completion
The purpose of this study is to evaluate whether C-myb Antisense (AS) Oligonucleotides (ODNs)is a possible treatment modality for advanced hematologic malignancies.